Sister Mary Joseph's Nodule - Clinical Aspests, Pathophysiology and Therapeutic Possibilities

Sister Mary Joseph’s nodule (SMJN) is an uncommon but clinically important cutaneous sign of visceral malignancy, presenting as metastatic involvement of the umbilicus. It is reported in approximately 1-3% of patients with intra-abdominal or pelvic neoplasms, most frequently originating from adenocarcinomas of the stomach, ovary, colon, or pancreas. Less common primary sites include the endometrium, gallbladder, lung, and prostate. The metastatic spread to the umbilical region can occur via several mechanisms, including direct peritoneal extension, lymphatic and hematogenous dissemination, or through embryonic remnants such as the urachus, the umbilical vein, and the falciform ligament. Clinically, SMJN manifests as a firm, irregular, and sometimes painful umbilical nodule, which may ulcerate or discharge serous or sanguinous fluid. In many cases, it represents the first visible sign of an otherwise occult malignancy, making its recognition of critical diagnostic value for dermatologists and other clinicians. As a readily accessible cutaneous marker, SMJN provides an opportunity for early suspicion of advanced intra-abdominal cancer, which can lead to timely imaging studies, biopsy, and referral for oncological evaluation. The prognosis associated with SMJN remains poor, with median survival reported between 6 and 12 months, reflecting its association with late-stage disease and widespread metastasis. Treatment is primarily palliative and depends on the type and extent of the underlying malignancy. Therapeutic strategies may include systemic chemotherapy, targeted therapy, or limited surgical excision for symptomatic relief, all within the framework of a multidisciplinary approach involving oncology, surgery, radiology, and dermatology. For dermatologists, awareness of SMJN is essential, as it underscores the role of the skin as a window to systemic disease. Prompt recognition and biopsy of suspicious umbilical lesions may not only establish the diagnosis but also provide critical information guiding further management. Although rare, SMJN remains a valuable clinical indicator that bridges dermatology and oncology, highlighting the importance of cutaneous examination in systemic malignancy.